Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v7-EN | Version v6-FR | |
|---|---|---|
| Language | English | French |
| Date Updated | 2020-09-19 | 2020-09-18 |
| Drug Identification Number | 02242905 | 02242905 |
| Brand name | MIDAZOLAM INJECTION | MIDAZOLAM INJECTION |
| Common or Proper name | Midazolam Injection | Midazolam Injection |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | MIDAZOLAM | MIDAZOLAM |
| Strength(s) | 5MG | 5MG |
| Dosage form(s) | LIQUID | LIQUID |
| Route of administration | INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS | INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS |
| Packaging size | 5 mg/mL, MD Vial, 2 mL | 5 mg/mL, MD Vial, 2 mL |
| ATC code | N05CD | N05CD |
| ATC description | HYPNOTICS AND SEDATIVES | HYPNOTICS AND SEDATIVES |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2020-08-04 | 2020-08-04 |
| Actual start date | ||
| Estimated end date | 2020-09-15 | 2020-09-15 |
| Actual end date | 2020-09-18 | 2020-09-18 |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Fresenius Kabi Canada Ltd. regrets to advise that due to a manufacturing delay, we will be encountering a supply interruption with our C410202 Midazolam Injection 5 mg/mL, MD Vial, 2 mL. Our C410210 Midazolam Injection 5 mg/mL, MD Vial, 10 mL format is available for substitution. Allocations for this code have been increased to cover the 2 mL demand. UPDATE SEP 18 2020 Fresenius Kabi Canada Ltd. is pleased to advise that replenishment inventories of our Midazolam Injection, 5 mg/mL, MD Vial, 2 mL will be available at all distribution centres by Friday, September 18, 2020. Please note this product will remain on allocation. Contract customers will be allocated 100% of their historical average monthly volumes. | Fresenius Kabi Canada Ltd. regrets to advise that due to a manufacturing delay, we will be encountering a supply interruption with our C410202 Midazolam Injection 5 mg/mL, MD Vial, 2 mL. Our C410210 Midazolam Injection 5 mg/mL, MD Vial, 10 mL format is available for substitution. Allocations for this code have been increased to cover the 2 mL demand. UPDATE SEP 18 2020 Fresenius Kabi Canada Ltd. is pleased to advise that replenishment inventories of our Midazolam Injection, 5 mg/mL, MD Vial, 2 mL will be available at all distribution centres by Friday, September 18, 2020. Please note this product will remain on allocation. Contract customers will be allocated 100% of their historical average monthly volumes. |
| Health Canada comments |